The COVID-19 pandemic accelerated a change that was already underway with regards to the digitisation of biopharma marketing – and the increasing ubiquity of omnichannel.
As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing.
A multichannel marketing approach, together with compelling content, is the ultimate way for pharma to deliver the message in the right way to its customers.
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio